Source-grounded facts extracted from Sonoma Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Sonoma Pharmaceuticals, Inc. entered into Underwriting Agreement with Dawson James Securities, Inc. (effective 2026-04-24).
“On April 24, 2026, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Dawson James Securities, Inc. (the “Underwriter”).”
Sonoma Pharmaceuticals, Inc. entered into Manufacturing and Supply Agreement with Kenvue Brands LLC (effective 2025-10-24).
“On April 8, 2026, we entered into a Manufacturing and Supply Agreement with Kenvue Brands LLC for the sale of Microcyn ® technology-based products in the United States.”
Sonoma Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“March 21, 2024, Sonoma Pharmaceuticals, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until September 16, 2024 to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the “Rule”). The Extension Notice has no immediate effect on the listing of the Company’s common stock. As previously disclosed in the”
Sonoma Pharmaceuticals, Inc. amended Amendment No. 1 with Maxim Group LLC valued at up to $785,679 (effective 2024-03-08).
“On March 8, 2024, the Company entered into an amendment to the Agreement (“Amendment No. 1”) to provide for the sale of up to $785,679 of additional shares under the Agreement.”
Sonoma Pharmaceuticals, Inc. entered into a license with NovaBay Pharmaceuticals, Inc. (effective 2024-01-05).
“Effective January 5, 2024, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into a license and distribution agreement with NovaBay Pharmaceuticals, Inc. for the sale and marketing of Avenova ® -branded products by the Company in the European Union.”
Sonoma Pharmaceuticals, Inc. entered into Equity Distribution Agreement with Maxim Group LLC valued at up to $392,077 (effective 2023-12-15).
“On December 15, 2023, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”), with Maxim Group LLC (“Maxim”), pursuant to which the Company may offer and sell, from time to time, through Maxim, as sales agent or principal, shares of its common stock, $0.0001 par value per share.”
Sonoma Pharmaceuticals, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-09-28 meeting.
“Proposal 3 – Ratification of the Appointment of Independent Registered Public Accounting Firm Our stockholders voted upon and approved the ratification of the appointment of Frazier & Deeter, LLC as our independent registered public accounting firm for the fiscal year ending March 31, 2024. The votes on this proposal were as follows: FOR AGAINST ABSTAIN 2,560,351 41,495 3,765”
Sonoma Pharmaceuticals, Inc. shareholders rejected Advisory Vote to Approve Executive Compensation at the 2023-09-28 meeting.
“Proposal 2 – Advisory Vote to Approve Executive Compensation Our stockholders voted upon and did not approve, by non-binding advisory vote, the compensation of our named executive officers for the year ended March 31, 2023, as described in our proxy statement dated July 27, 2023. The votes on this proposal were as follows: FOR AGAINST ABSTAIN 560,065 290,657 8,188”
Sonoma Pharmaceuticals, Inc. shareholders approved Election of One Class III Director at the 2023-09-28 meeting.
“Proposal 1 – Election of One Class III Director Mr. Jerry McLaughlin was duly elected as our Class III director. The results of the election were as follows: NOMINEE FOR WITHHELD Jerry McLaughlin 552,672 306,238”
Sonoma Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“September 22, 2023, we received a letter from the Listing Qualifications staff of The Nasdaq Stock Market LLC, notifying us that, for the previous 30 consecutive business days, we have failed to comply with Nasdaq Listing Rule 5550(a)(2), which requires us to maintain a minimum bid price of $1 per share for our common stock. In accordance with Listing Rule 5810(c)(3)(A), Nasdaq has granted us a period of 180 calendar days, or until March 20, 2024, to regain compliance with the Rule. We may regain compliance with the Rule at any time during this compliance period if the minimum bid price for ou”
John Dal Poggetto was appointed as Controller at Sonoma Pharmaceuticals, Inc..
“Effective July 17, 2023, our Board of Directors appointed John Dal Poggetto as our Controller.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.